Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab

References

• Dignass A Eliakim R Magro F Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis J Crohns Colitis 2012 6 10 965 990 23040452
   PubMed Web of Science ®Google Scholar
• Silverberg MS Satsangi J Ahmad T Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology Can J Gastroenterol 2005 19 Suppl A 5 36 16151544
   PubMed Web of Science ®Google Scholar
• Ekbom A Helmick C Zack M Adami HO Ulcerative colitis and colorectal cancer. A population-based study N Engl J Med 1990 323 18 1228 1233 2215606
   PubMed Web of Science ®Google Scholar
• Solberg IC Lygren I Jahnsen J IBSEN Study Group Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study) Scand J Gastroenterol 2009 44 4 431 440 19101844
   PubMed Web of Science ®Google Scholar
• D’Haens G Sandborn WJ Feagan BG A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis Gastroenterology 2007 132 2 763 786 17258735
   PubMed Web of Science ®Google Scholar
• Ford AC Achkar JP Khan KJ Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis Am J Gastroenterol 2011 106 4 601 616 21407188
   PubMed Web of Science ®Google Scholar
• Dignass A Lindsay JO Sturm A Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management J Crohns Colitis 2012 6 10 991 1030 23040451
   PubMed Web of Science ®Google Scholar
• Rutgeerts P Sandborn WJ Feagan BG infliximab for induction and maintenance therapy for ulcerative colitis N Engl J Med 2005 353 23 2462 2476 16339095
   PubMed Web of Science ®Google Scholar
• Ardizzone S Maconi G Russo A Imbesi V Colombo E Bianchi Porro G Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis Gut 2006 55 1 47 53 15972298
   PubMed Web of Science ®Google Scholar
• Panaccione R Rutgeerts P Sandborn WJ Feagan B Schreiber S Ghosh S Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease Aliment Pharmacol Ther 2008 28 6 674 688 18532990
   PubMed Web of Science ®Google Scholar
• Armuzzi A Pugliese D Danese S Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopic remission Inflamm Bowel Dis Epub 2 27 2013
   Web of Science ®Google Scholar
• Laharie D Bourreille A Branche J Groupe d’Etudes Thérapeutiques des Affections Inflammatoires Digestives Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial Lancet 2012 380 9857 1909 1915 23063316
   PubMed Web of Science ®Google Scholar
• Moskovitz DN Van Assche G Maenhout B Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis Clin Gastroenterol Hepatol 2006 4 6 760 765 16716758
   PubMed Web of Science ®Google Scholar
• HUMIRA® (adalimumab) subcutaneous injection [product monograph] North Chicago, IL Abbott Laboratories, Ltd 2012
   Google Scholar
• Hanauer SB Sandborn WJ Rutgeerts P Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial Gastroenterology 2006 130 2 323 333 16472588
   PubMed Web of Science ®Google Scholar
• Colombel JF Sandborn WJ Rutgeerts P Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial Gastroenterology 2007 132 1 52 65 17241859
   PubMed Web of Science ®Google Scholar
• Sandborn WJ Rutgeerts P Enns R Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial Ann Intern Med 2007 146 12 829 838 17470824
   PubMed Web of Science ®Google Scholar
• Panaccione R Colombel JF Sandborn WJ Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn’s disease Aliment Pharmacol Ther 2010 31 12 1296 1309 20298496
   PubMed Web of Science ®Google Scholar
• Colombel JF Schwartz DA Sandborn WJ Adalimumab for the treatment of fistulas in patients with Crohn’s disease Gut 2009 58 7 940 948 19201775
   PubMed Web of Science ®Google Scholar
• Reinisch W Sandborn WJ Hommes DW Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial Gut 2011 60 6 780 787 21209123
   PubMed Web of Science ®Google Scholar
• Sandborn WJ van Assche G Reinisch W Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis Gastroenterology 2012 142 2 257 265 22062358
   PubMed Web of Science ®Google Scholar
• Reinisch W Sandborn WJ Kumar A Pollack PF Lazar A Thakkar RB 52-week clinical efficacy with adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppresants Gut 2011 60 Suppl 1 A139 A140
   Web of Science ®Google Scholar
• Sandborn WJ Colombel JF D’Haens G One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2 Aliment Pharmacol Ther 2013 37 2 204 213 23173821
   PubMed Web of Science ®Google Scholar
• Feagan BG Sandborn WJ Thakkar RB Adalimumab induction dose reduces the risk of hospitalizations and colectomies in patients with ulcerative colitis during the first 8 weeks of therapy Gut 2012 61 Suppl 3 A283
   Google Scholar
• Feagan BG Sandborn WJ Skup M Adalimumab therapy reduces hospitalization and colectomy rates in patients with ulcerative colitis among initial responders Gut 2012 61 Suppl 3 A164
   Google Scholar
• Colombel JF Sandborn WJ Wolf D Long term efficacy of adalimumab for treatment of moderate to severe ulcerative colitis Gut 2012 61 Suppl 3 A80
   Google Scholar
• Oussalah A Laclotte C Chevaux JB Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience Aliment Pharmacol Ther 2008 28 8 966 972 18652603
   PubMed Web of Science ®Google Scholar
• AFC W Leighton JA Hanauer SB Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab Inflamm Bowel Dis 2009 15 9 1302 1307 19408340
   PubMed Web of Science ®Google Scholar
• Hudis N Rajca B Polyak S Zeilman CJ Valentine JF The outcome of active ulcerative colitis treated with adalimumab Gastroenterology 2009 136 5 Suppl 1 A661
   Web of Science ®Google Scholar
• Gies N Kroeker KI Wong K Fedorak RN Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort Aliment Pharmacol Ther 2010 32 4 522 528 20500733
   PubMed Web of Science ®Google Scholar
• Taxonera C Estellés J Fernández-Blanco I Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab Aliment Pharmacol Ther 2011 33 3 340 348 21133961
   PubMed Web of Science ®Google Scholar
• McDermott E Murphy S Keegan D O’Donoghue D Mulcahy H Doherty G Efficacy of adalimumab as a long term maintenance therapy in ulcerative colitis J Crohns Colitis 2013 7 2 150 153 22520592
   PubMed Web of Science ®Google Scholar
• Ferrante M Karmiris K Compernolle G Efficacy of adalimumab in patients with ulcerative colitis: restoration of serum levels after dose escalation results in a better long-term outcome Gut 2011 60 Suppl 3 A72
   Google Scholar
• García-Bosch O Gisbert JP Canas-Ventura A Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome J Crohns Colitis 2012 Epub 11 8 2012
   Web of Science ®Google Scholar
• Armuzzi A Biancone L Daperno M Adalimumab in active ulcerative colitis: a “real-life” observational study Dig Liver Dis 2013
   Google Scholar
• Burmester GR Mease P Dijkmans BA Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases Ann Rheum Dis 2009 68 12 1863 1869 19147611
   PubMed Web of Science ®Google Scholar
• Karmiris K Paintaud G Noman M Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn’s disease Gastroenterology 2009 137 5 1628 1640 19664627
   PubMed Web of Science ®Google Scholar